Latigo Biotherapeutics
Company profile
Primary focus
Developing non-opioid pain medicines.
Why it’s included
The company explicitly develops novel, non-opioid, selective Nav1.8 inhibitors for acute pain, including intravenous and oral formulations for perioperative and hospital settings, directly addressing the need for new molecular entities for acute pain relief without opioid liabilities.
Relevant capabilities
- Early clinical development and Phase 1 trial execution (SAD/MAD)
- Target selection using human genetics and human pharmacology
- Use of human neuronal model systems for target validation and target engagement
- Selectivity profiling across ion channel isoforms
- Patch clamp electrophysiology infrastructure for rapid bioactivity profiling
Commercial sectorVoltage-Gated Ion Channel Inhibitors
Technology classesNav1.8 voltage-gated sodium channel inhibitors, Alternative formulations for rapid-onset non-opioid analgesia
Relevant commercial products
- Oral selective Nav1.8 inhibitor — clinical candidate for acute pain
- Onzotrigine IV
- LTG-418
- Onzotrigine (LTG-001)
- Oral selective Nav1.8 inhibitor — clinical candidate for chronic pain